drugset / Trial / NCT05320133
Jinghua Weikang Capsule Containing Quadruple Therapy for IgAN With Helicobacter Pylori Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is to evaluate the efficacy and safety of the Jinghua Weikang Capsule (a Chinese patent medicine for peptic ulcer and gastritis) containing quadruple therapy (Jinghua Weikang Caplsule plus triple therpy) for eradicating Helicobacter pylori in IgA nephropathy.
Timeline
- Start
- 2022-06-20
- Primary completion
- 2024-11-30
- Completion
- 2024-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bismuth Potassium Citrate | Unknown | 220 mg | — |
| Subject | Jinghua Weikang Capsule | Traditional medicine (herbal / TCM) | 240 mg | — |
| Background | Clarithromycin | Small molecule | 500 mg | — |
| Background | Rabeprazole | Small molecule | 10 mg | — |
| Background | moxycillin | Unknown | 1 g | — |